S L Greenspan1, K T Vujevich2, A Brufsky2, B C Lembersky2, G J van Londen2, R C Jankowitz2, S L Puhalla2, P Rastogi2, S Perera2,3. 1. Department of Medicine, University of Pittsburgh, 3471 Fifth Ave., Suite 1110, Kaufmann Bldg, Pittsburgh, PA, 15213, USA. greenspn@pitt.edu. 2. Department of Medicine, University of Pittsburgh, 3471 Fifth Ave., Suite 1110, Kaufmann Bldg, Pittsburgh, PA, 15213, USA. 3. Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract
UNLABELLED: In postmenopausal women with low bone mass and hormone-receptor-positive breast cancer on anaromatase inhibitor, risedronate maintained skeletal health assessed by bone density and turnover markers. Women with the greatest decreases in bone turnover markers at 12 months had the greatest increases in bone density at 24 months. INTRODUCTION:Aromatase inhibitors (AIs), adjuvant endocrine therapy for postmenopausal women with hormone-receptor-positive breast cancer, are associated with bone loss and fractures. Our objectives were to determine if (1) oral bisphosphonate therapy can prevent bone loss in women on an AI and (2) early changes in bone turnover markers (BTM) can predict later changes in bone mineral density (BMD). METHODS: We conducted a 2-year double-blind, placebo-controlled, randomized trial in 109 postmenopausal women with low bone mass on anAI (anastrozole, letrozole, or exemestane) for hormone-receptor-positive breast cancer. Participants were randomized to once weekly risedronate 35 mg or placebo, and all received calcium plus vitamin D. The main outcome measures included BMD, BTM [carboxy-terminal collagen crosslinks (CTX) and N-terminal propeptide of type 1 procollagen (P1NP)], and safety. RESULTS: Eighty-seven percent completed 24 months. BMD increased more in the active treatment group compared to placebo with an adjusted difference at 24 months of 3.9 ± 0.7 percentage points at the spine and 3.2 ± 0.5 percentage points at the hip (both p < 0.05). The adjusted difference between the active treatment and placebo groups were 0.09 ± 0.04 nmol/LBCE for CTX and 23.3 ± 4.8 μg/mL for P1NP (both p < 0.05). Women with greater 12-month decreases in CTX and P1NP in the active treatment group had a greater 24-month increase in spinal BMD (p < 0.05). The oral therapy was safe and well tolerated. CONCLUSION: In postmenopausal women with low bone mass and breast cancer on an AI, the oral bisphosphonate risedronate maintained skeletal health.
RCT Entities:
UNLABELLED: In postmenopausal women with low bone mass and hormone-receptor-positive breast cancer on an aromatase inhibitor, risedronate maintained skeletal health assessed by bone density and turnover markers. Women with the greatest decreases in bone turnover markers at 12 months had the greatest increases in bone density at 24 months. INTRODUCTION:Aromatase inhibitors (AIs), adjuvant endocrine therapy for postmenopausal women with hormone-receptor-positive breast cancer, are associated with bone loss and fractures. Our objectives were to determine if (1) oral bisphosphonate therapy can prevent bone loss in women on an AI and (2) early changes in bone turnover markers (BTM) can predict later changes in bone mineral density (BMD). METHODS: We conducted a 2-year double-blind, placebo-controlled, randomized trial in 109 postmenopausal women with low bone mass on an AI (anastrozole, letrozole, or exemestane) for hormone-receptor-positive breast cancer. Participants were randomized to once weekly risedronate 35 mg or placebo, and all received calcium plus vitamin D. The main outcome measures included BMD, BTM [carboxy-terminal collagen crosslinks (CTX) and N-terminal propeptide of type 1 procollagen (P1NP)], and safety. RESULTS: Eighty-seven percent completed 24 months. BMD increased more in the active treatment group compared to placebo with an adjusted difference at 24 months of 3.9 ± 0.7 percentage points at the spine and 3.2 ± 0.5 percentage points at the hip (both p < 0.05). The adjusted difference between the active treatment and placebo groups were 0.09 ± 0.04 nmol/LBCE for CTX and 23.3 ± 4.8 μg/mL for P1NP (both p < 0.05). Women with greater 12-month decreases in CTX and P1NP in the active treatment group had a greater 24-month increase in spinal BMD (p < 0.05). The oral therapy was safe and well tolerated. CONCLUSION: In postmenopausal women with low bone mass and breast cancer on an AI, the oral bisphosphonaterisedronate maintained skeletal health.
Entities:
Keywords:
Antiresorptives; Biochemical markers of bone turnover; Clinical trials; DXA
Authors: Adam M Brufsky; W Graydon Harker; J Thaddeus Beck; Linda Bosserman; Charles Vogel; Christopher Seidler; Lixian Jin; Ghulam Warsi; Eliza Argonza-Aviles; John Hohneker; Solveig G Ericson; Edith A Perez Journal: Cancer Date: 2011-10-10 Impact factor: 6.860
Authors: Per E Lønning; Jürgen Geisler; Lars E Krag; Bjørn Erikstein; Yngve Bremnes; Anne I Hagen; Ellen Schlichting; Ernst A Lien; Erik S Ofjord; Jolanda Paolini; Anna Polli; Giorgio Massimini Journal: J Clin Oncol Date: 2005-06-27 Impact factor: 44.544
Authors: Susan L Greenspan; Adam Brufsky; Barry C Lembersky; Rajib Bhattacharya; Karen T Vujevich; Subashan Perera; Susan M Sereika; Victor G Vogel Journal: J Clin Oncol Date: 2008-04-21 Impact factor: 44.544
Authors: Taryn Becker; Lorraine Lipscombe; Steven Narod; Christine Simmons; Geoffrey M Anderson; Paula A Rochon Journal: J Am Geriatr Soc Date: 2012-09 Impact factor: 5.562
Authors: Ivana Sestak; Shalini Singh; Jack Cuzick; Glen M Blake; Rajesh Patel; Fatma Gossiel; Rob Coleman; Mitch Dowsett; John F Forbes; Anthony Howell; Richard Eastell Journal: Lancet Oncol Date: 2014-11-11 Impact factor: 41.316
Authors: William D Leslie; Suzanne N Morin; Lisa M Lix; Saroj Niraula; Eugene V McCloskey; Helena Johansson; Nicholas C Harvey; John A Kanis Journal: Oncologist Date: 2019-07-10
Authors: Peyman Hadji; Matti S Aapro; Jean-Jacques Body; Michael Gnant; Maria Luisa Brandi; Jean Yves Reginster; M Carola Zillikens; Claus-C Glüer; Tobie de Villiers; Rod Baber; G David Roodman; Cyrus Cooper; Bente Langdahl; Santiago Palacios; John Kanis; Nasser Al-Daghri; Xavier Nogues; Erik Fink Eriksen; Andreas Kurth; Rene Rizzoli; Robert E Coleman Journal: J Bone Oncol Date: 2017-03-23 Impact factor: 4.072
Authors: Komal Waqas; Joana Lima Ferreira; Elena Tsourdi; Jean-Jacques Body; Peyman Hadji; M C Zillikens Journal: J Bone Oncol Date: 2021-03-18 Impact factor: 4.072